Glenmark Life Sciences, a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas, announces its change of identity to Alivus Life Sciences, marking an exciting new chapter in its journey. This is consequent to the acquisition by Nirma Limited, a diversified conglomerate with interest in consumer products, chemicals, and pharmaceuticals.
The change is reflective of the company's evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space. The new identity, Alivus Life Sciences, represents vitality and growth with a renewed focus. It embodies the optimism and transformation the company is embracing as it enters the next phase of its journey.
Key Changes
Corporate Identity: Alivus Life Sciences Limited (Formerly Glenmark Life Sciences Limited)
Stock Exchange Scrip
On NSE: ALIVUS (NSE symbol changes from 'GLS' to 'ALIVUS', effective January 20, 2025)
On BSE: 543322 (BSE Code remains the same)
Website: The official website is now alivus.com, providing comprehensive information about the company's updated brand identity, services and initiatives.
This rebranding to Alivus Life Sciences marks an important milestone in the company's journey. It symbolizes our commitment to enhancing services for our customers, stakeholders, and employees. While the company's name has changed, its dedication to quality and innovation remains steadfast.
Shares of Glenmark Life Sciences Ltd was last trading in BSE at Rs. 1085.80 as compared to the previous close of Rs. 1075.80. The total number of shares traded during the day was 11298 in over 1363 trades.
The stock hit an intraday high of Rs. 1098.00 and intraday low of 1059.05. The net turnover during the day was Rs. 12157326.00. |
